CELZ
Creative Medical Technology Holdings, Inc.
Price Chart
Latest Quote
$2.23
-0.01 (-0.45%)
Current Price
| Previous Close | $2.24 |
| Open | $2.21 |
| Day High | $2.32 |
| Day Low | $2.21 |
| Volume | 94,055 |
Stock Information
| Shares Outstanding | 3.70M |
| Total Debt | $14K |
| Cash Equivalents | $5.85M |
| Revenue | $3K |
| Net Income | $-5.76M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $8.24M |
| EPS (TTM) | $-2.07 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $2.47M |
| Sales | $3K |
| Income | $-5.76M |
| Book/sh | $1.65 |
| Cash/sh | $1.58 |
| Employees | 4 |
Financial Ratios
| Quick Ratio | 19.01 |
| Current Ratio | 19.69 |
| Debt/Eq | 0.23 |
Returns & Margins
| ROA | -50.22% |
| ROE | -81.17% |
| Gross Margin | 66.87% |
| Operating Margin | -198049.65% |
Ownership
| Insider Ownership | 0.95% |
| Institutional Ownership | 6.50% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.48 |
| P/S | 2747.86 |
| P/B | 1.35 |
Analyst Data
| Recommendation | none |
| Target Price | $20.00 |
Technical Indicators
| SMA20 | $2.23 |
| SMA50 | $2.24 |
| SMA200 | $2.49 |
| RSI | 48.78 |
| ATR | 0.1506 |
| Shares Float | 3.43M |
| Short Float | 3.72% |
| Short Ratio | 2.97 |
| Volatility | 1.83 |
| Rel Volume | 1.49 |
Performance History
| Week | +4.69% |
| Month | +1.83% |
| Quarter | +18.62% |
| 6 Months | +6.70% |
| YTD | +13.20% |
| Year | -0.45% |
| 3 Years | -53.35% |
| 5 Years | -98.86% |
| 10 Years | -100.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $2.23 | 96,500 |
| 2026-06-17 | $2.24 | 42,900 |
| 2026-06-16 | $2.24 | 284,400 |
| 2026-06-15 | $2.39 | 81,800 |
| 2026-06-12 | $2.17 | 17,800 |
| 2026-06-11 | $2.13 | 27,700 |
| 2026-06-10 | $2.11 | 15,600 |
| 2026-06-09 | $2.18 | 19,400 |
| 2026-06-08 | $2.17 | 30,900 |
| 2026-06-05 | $2.06 | 65,200 |
| 2026-06-04 | $2.12 | 43,100 |
| 2026-06-03 | $2.20 | 72,500 |
| 2026-06-02 | $2.23 | 169,300 |
| 2026-06-01 | $2.25 | 43,200 |
| 2026-05-29 | $2.25 | 68,000 |
| 2026-05-28 | $2.26 | 25,800 |
| 2026-05-27 | $2.31 | 31,800 |
| 2026-05-26 | $2.34 | 61,600 |
| 2026-05-22 | $2.39 | 47,700 |
| 2026-05-21 | $2.30 | 52,900 |
| 2026-05-20 | $2.27 | 63,600 |
| 2026-05-19 | $2.19 | 50,900 |
About Creative Medical Technology Holdings, Inc.
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, a platform to treat infertility as a result of premature ovarian failure; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
đ° Latest News
Creative Medical Technology opens nationwide burn-pit data registry
Proactive âĸ 2026-06-16T19:49:00Z
Analysts Expect Breakeven For Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Before Long
Simply Wall St. âĸ 2026-04-09T10:56:56Z
Bears are Losing Control Over Creative Medical Technology Holdings, Inc. (CELZ), Here's Why It's a 'Buy' Now
Zacks âĸ 2025-11-05T14:55:01Z
Market Sentiment Around Loss-Making Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ)
Simply Wall St. âĸ 2025-10-31T10:39:00Z
Creative Medical Technology Holdings Second Quarter 2025 Earnings: US$0.48 loss per share (vs US$1.11 loss in 2Q 2024)
Simply Wall St. âĸ 2025-08-11T10:01:07Z
New Strong Sell Stocks for July 31st
Zacks âĸ 2025-07-31T09:43:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $2,194 | $4,400 | $3,600 | $28,491 |
| Cost Of Revenue | $2,194 | $4,400 | $3,600 | $28,491 |
| Total Revenue | $6,000 | $11,000 | $9,000 | $88,600 |
| Operating Revenue | $6,000 | $11,000 | $9,000 | $88,600 |
| Expenses | ||||
| Total Expenses | $6,148,814 | $5,754,861 | $5,629,132 | $10,332,972 |
| Net Non Operating Interest Income Expense | $147,806 | $250,380 | $333,558 | $100,328 |
| Operating Expense | $6,146,620 | $5,750,461 | $5,625,532 | $10,304,481 |
| Interest Expense | - | - | - | $0 |
| Interest Expense Non Operating | - | - | - | $0 |
| Other Income Expense | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-5,995,008 | $-5,493,481 | $-5,286,574 | $-10,144,044 |
| Net Interest Income | $147,806 | $250,380 | $333,558 | $100,328 |
| Interest Income | $147,806 | $250,380 | $333,558 | $100,328 |
| Normalized Income | $-5,995,008 | $-5,493,481 | $-5,286,574 | $-10,144,044 |
| Net Income From Continuing And Discontinued Operation | $-5,995,008 | $-5,493,481 | $-5,286,574 | $-10,144,044 |
| Total Operating Income As Reported | $-6,142,814 | $-5,743,861 | $-5,620,132 | $-10,244,372 |
| Net Income Common Stockholders | $-5,995,008 | $-5,493,481 | $-5,286,574 | $-10,144,044 |
| Net Income | $-5,995,008 | $-5,493,481 | $-5,286,574 | $-10,144,044 |
| Net Income Including Noncontrolling Interests | $-5,995,008 | $-5,493,481 | $-5,286,574 | $-10,144,044 |
| Net Income Continuous Operations | $-5,995,008 | $-5,493,481 | $-5,286,574 | $-10,144,044 |
| Pretax Income | $-5,995,008 | $-5,493,481 | $-5,286,574 | $-10,144,044 |
| Interest Income Non Operating | $147,806 | $250,380 | $333,558 | $100,328 |
| Operating Income | $-6,142,814 | $-5,743,861 | $-5,620,132 | $-10,244,372 |
| Depreciation Amortization Depletion Income Statement | $123,327 | $110,452 | $94,584 | $92,084 |
| Depreciation And Amortization In Income Statement | $123,327 | $110,452 | $94,584 | $92,084 |
| Amortization Of Intangibles Income Statement | $123,327 | $110,452 | $94,584 | $92,084 |
| Gross Profit | $3,806 | $6,600 | $5,400 | $60,109 |
| Special Income Charges | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-2.52 | $-3.71 | $-3.76 | $-9.28 |
| Basic EPS | $-2.52 | $-3.71 | $-3.76 | $-9.28 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-6,019,487 | $-5,633,409 | $-5,525,548 | $-10,152,288 |
| Reconciled Depreciation | $123,327 | $110,452 | $94,584 | $92,084 |
| EBITDA (Bullshit earnings) | $-6,019,487 | $-5,633,409 | $-5,525,548 | $-10,152,288 |
| EBIT | $-6,142,814 | $-5,743,861 | $-5,620,132 | $-10,244,372 |
| Diluted Average Shares | $2,382,797 | $1,480,420 | $1,407,632 | $1,093,204 |
| Basic Average Shares | $2,382,797 | $1,480,420 | $1,407,632 | $1,093,204 |
| Diluted NI Availto Com Stockholders | $-5,995,008 | $-5,493,481 | $-5,286,574 | $-10,144,044 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Amortization | $123,327 | $110,452 | $94,584 | $92,084 |
| Research And Development | $2,259,796 | $2,400,777 | $1,970,639 | $6,268,854 |
| Selling General And Administration | $3,763,497 | $3,239,232 | $3,560,309 | $3,943,543 |
| Total Unusual Items | - | - | - | $0 |
| Total Unusual Items Excluding Goodwill | - | - | - | $0 |
| Other Special Charges | - | - | - | - |
| Gain On Sale Of Security | - | - | - | - |
Fetched: 2026-06-16
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $7,107,415 | $5,810,940 | $9,902,785 | $15,429,079 |
| Total Assets | $7,809,525 | $6,669,143 | $10,715,190 | $19,186,326 |
| Total Non Current Assets | $410,511 | $533,840 | $444,292 | $438,876 |
| Other Non Current Assets | $3,281 | $3,281 | $3,281 | $3,281 |
| Goodwill And Other Intangible Assets | $407,230 | $530,559 | $441,011 | $435,595 |
| Other Intangible Assets | $407,230 | $530,559 | $441,011 | $435,595 |
| Current Assets | $7,399,014 | $6,135,303 | $10,270,898 | $18,747,450 |
| Other Current Assets | $138,804 | $192,707 | $277,246 | $338,120 |
| Inventory | $0 | $2,194 | $6,594 | $10,194 |
| Receivables | $52,084 | $0 | - | $0 |
| Notes Receivable | $52,084 | $0 | - | - |
| Cash Cash Equivalents And Short Term Investments | $7,208,126 | $5,940,402 | $9,987,058 | $18,399,136 |
| Cash And Cash Equivalents | $7,208,126 | $5,940,402 | $3,466,867 | $8,320,519 |
| Cash Financial | $7,208,126 | $5,940,402 | $3,466,867 | $8,320,519 |
| Prepaid Assets | - | - | - | $338,120 |
| Accounts Receivable | - | - | - | $0 |
| Cash Equivalents | - | - | - | $10,078,617 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $284,880 | $327,644 | $371,394 | $3,321,652 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $0 |
| Current Liabilities | $284,880 | $327,644 | $371,394 | $3,321,652 |
| Payables And Accrued Expenses | $284,880 | $327,644 | $371,394 | $3,321,652 |
| Payables | $284,880 | $287,724 | $331,474 | $3,281,732 |
| Accounts Payable | $270,686 | $273,530 | $317,280 | $3,267,538 |
| Equity | ||||
| Common Stock Equity | $7,514,645 | $6,341,499 | $10,343,796 | $15,864,674 |
| Total Equity Gross Minority Interest | $7,524,645 | $6,341,499 | $10,343,796 | $15,864,674 |
| Stockholders Equity | $7,514,645 | $6,341,499 | $10,343,796 | $15,864,674 |
| Retained Earnings | $-70,586,921 | $-64,591,913 | $-59,098,432 | $-53,811,858 |
| Other | ||||
| Treasury Shares Number | $5,000 | $0 | $57,500 | - |
| Ordinary Shares Number | $3,696,668 | $1,748,428 | $1,373,626 | $1,407,623 |
| Share Issued | $3,701,668 | $1,748,428 | $1,431,126 | $1,407,623 |
| Tangible Book Value | $7,107,415 | $5,810,940 | $9,902,785 | $15,429,079 |
| Invested Capital | $7,514,645 | $6,341,499 | $10,343,796 | $15,864,674 |
| Working Capital | $7,114,134 | $5,807,659 | $9,899,504 | $15,425,798 |
| Total Capitalization | $7,514,645 | $6,341,499 | $10,343,796 | $15,864,674 |
| Minority Interest | $10,000 | $0 | - | - |
| Treasury Stock | $10,000 | $0 | $270,952 | $0 |
| Additional Paid In Capital | $78,108,422 | $70,931,663 | $69,711,749 | $69,675,125 |
| Capital Stock | $3,144 | $1,749 | $1,431 | $1,407 |
| Common Stock | $3,144 | $1,749 | $1,431 | $1,407 |
| Preferred Stock | $0 | $0 | $0 | - |
| Current Accrued Expenses | $0 | $39,920 | $39,920 | $39,920 |
| Dueto Related Parties Current | $14,194 | $14,194 | $14,194 | $14,194 |
| Other Short Term Investments | - | $0 | $6,520,191 | $10,078,617 |
Fetched: 2026-06-16
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-5,856,445 | $-5,501,292 | $-8,127,885 | $-7,796,966 |
| Operating Activities | ||||
| Operating Cash Flow | $-5,856,445 | $-5,301,292 | $-8,027,885 | $-7,796,966 |
| Cash Flow From Continuing Operating Activities | $-5,856,445 | $-5,301,292 | $-8,027,885 | $-7,796,966 |
| Operating Gains Losses | - | - | $-34,087 | - |
| Investing Activities | ||||
| Investing Cash Flow | $-50,500 | $6,320,191 | $3,445,185 | $-10,078,617 |
| Cash Flow From Continuing Investing Activities | $-50,500 | $6,320,191 | $3,445,185 | $-10,078,617 |
| Net Other Investing Changes | $-50,500 | - | - | - |
| Capital Expenditure | - | $-200,000 | $-100,000 | - |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-10,000 | $-174,964 | $-270,952 | $0 |
| Issuance Of Capital Stock | $7,174,669 | $1,629,600 | $0 | $15,471,775 |
| Financing Cash Flow | $7,174,669 | $1,454,636 | $-270,952 | $15,472,232 |
| Cash Flow From Continuing Financing Activities | $7,174,669 | $1,454,636 | $-270,952 | $15,472,232 |
| Net Other Financing Charges | $10,000 | - | - | - |
| Net Preferred Stock Issuance | $0 | $100 | $0 | $0 |
| Preferred Stock Issuance | $0 | $100 | $0 | $0 |
| Net Common Stock Issuance | $7,164,669 | $1,454,536 | $-270,952 | $15,471,775 |
| Common Stock Issuance | $7,174,669 | $1,629,500 | $0 | $15,471,775 |
| Other | ||||
| Interest Paid Supplemental Data | $0 | $0 | $0 | $0 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $7,208,126 | $5,940,402 | $3,466,867 | $8,320,519 |
| Beginning Cash Position | $5,940,402 | $3,466,867 | $8,320,519 | $10,723,870 |
| Changes In Cash | $1,267,724 | $2,473,535 | $-4,853,652 | $-2,403,351 |
| Common Stock Payments | $-10,000 | $-174,964 | $-270,952 | $0 |
| Net Investment Purchase And Sale | $0 | $6,520,191 | $3,545,185 | $-10,078,617 |
| Sale Of Investment | $0 | $6,520,191 | $26,400,000 | $0 |
| Net Intangibles Purchase And Sale | $0 | $-200,000 | $-100,000 | $0 |
| Purchase Of Intangibles | $0 | $-200,000 | $-100,000 | $0 |
| Change In Working Capital | $13,335 | $45,089 | $-2,838,456 | $2,186,248 |
| Change In Other Current Liabilities | $0 | $0 | - | - |
| Change In Payables And Accrued Expense | $-42,762 | $-43,850 | $-2,950,258 | $2,521,211 |
| Change In Accrued Expense | $-39,920 | $0 | $0 | $15,535 |
| Change In Payable | $-2,842 | $-43,850 | $-2,950,258 | $2,505,676 |
| Change In Account Payable | $-2,842 | $-43,850 | $-2,950,258 | $2,505,676 |
| Change In Prepaid Assets | $53,903 | $84,539 | $108,202 | $-338,120 |
| Change In Inventory | $2,194 | $4,400 | $3,600 | $672 |
| Other Non Cash Items | $-1,584 | - | - | - |
| Stock Based Compensation | $3,485 | $36,648 | $36,648 | $68,746 |
| Depreciation Amortization Depletion | $123,327 | $110,452 | $94,584 | $92,084 |
| Depreciation And Amortization | $123,327 | $110,452 | $94,584 | $92,084 |
| Amortization Cash Flow | $123,327 | $110,452 | $94,584 | $92,084 |
| Amortization Of Intangibles | $123,327 | $110,452 | $94,584 | $92,084 |
| Net Income From Continuing Operations | $-5,995,008 | $-5,493,481 | $-5,286,574 | $-10,144,044 |
| Purchase Of Investment | - | $0 | $-22,854,815 | $-10,078,617 |
| Proceeds From Stock Option Exercised | - | - | $0 | $457 |
| Change In Receivables | - | - | $0 | $2,485 |
| Changes In Account Receivables | - | - | $0 | $2,485 |
| Gain Loss On Investment Securities | - | - | $-34,087 | - |
| Repayment Of Debt | - | - | - | $0 |
| Issuance Of Debt | - | - | - | $0 |
| Preferred Stock Payments | - | - | - | $0 |
| Net Issuance Payments Of Debt | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Payments | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |
| Provisionand Write Offof Assets | - | - | - | $0 |
Fetched: 2026-06-16